In-depth cooperation with Beijing Jianguo Medical, Brain Act Aurora (06681.HK) reaches a new milestone
Neural Aurora (06681.HK) has been making frequent moves recently, with overseas business expansion and domestic technology collaborations being announced intensively. The group recently announced that its indirectly wholly-owned subsidiary, Zhejiang Neural Aurora Medical Technology, has officially signed the "Cognitive Digital Therapy Project Cooperation Agreement" with Beijing Jianguo Medical Technology. From January 1, 2026, to December 30, 2026, the two parties will conduct in-depth cooperation around the topic of "Construction and Promotion of Cognitive Function Assessment and Training in Mental Health Application Scenarios," jointly promoting the standardization, scalability, and accessibility of digital therapies for cognitive disorders.
This collaboration is a profound affirmation of Neural Aurora. The parent company of Beijing Jianguo Medical, Beijing Jianguo Technology Group, was established in 1994 and is a nationally recognized enterprise technology center with over 4,800 employees and a nationwide R&D, production, and service network. Beijing Jianguo focuses on the clinical transformation and promotion of rehabilitation medical technologies. This collaboration is a practical integration of cutting-edge digital diagnosis and treatment algorithms with a mature industrial system, aiming to jointly advance the standardized application and large-scale implementation of digital therapies for cognitive disorders.
The main contents of the collaboration include: 1. National Standard Research: Jointly develop the core technical indicator system, clinical validation pathways, and application standards for digital therapies for cognitive disorders, providing evidence-based data and draft texts for national standard projects.
2. Multi-Center Pilot: Simultaneously implement the "Neural Aurora Cognitive Function Assessment and Training System" in mental health welfare institutions and communities in Hangzhou, Nanning, Wuhan, Mudanjiang, and other locations, covering an estimated 80% of the target institutions and forming replicable intervention pathways.
3. Research Projects: Establish long-term research cohorts across institutions, regions, and scenarios, with all data jointly owned by the research parties and Zhejiang Neural Aurora Medical Technology, to be used for subsequent policy formulation, technological upgrades, and standard iterations.
The above projects, taking cognitive function assessment and training as the entry point, focus on practical issues such as insufficient service capabilities and inconsistent technical pathways for cognitive disorders in the mental health and social welfare systems. Through national standard formulation, research project guidance, and multi-scenario application validation, they aim to gradually form replicable and scalable digital therapy application models to serve a broader population.
This collaboration is of great significance to Neural Aurora. First, through the partnership with Beijing Jianguo Medical, it delves into the specific application scenario of mental health, exploring and validating innovative models for digital therapies in assessment, training, and management pathways. This will help the company deeply integrate cutting-edge AI algorithms with clinical needs, fostering more precise and universally applicable technological products and expanding the application boundaries of digital therapies in mental health.
Second, Neural Aurora's participation in national standard research and multi-center sample validation will not only help accumulate high-level evidence-based medical evidence but also directly shape industry standards. This will enhance the industry recognition and authority of its solutions, laying a solid foundation for the large-scale promotion of its products nationwide.
Additionally, the project focuses on mental health welfare institutions and community scenarios, aiming to improve the service capabilities for cognitive disorders at the grassroots and specific institutional levels. Successful implementation will significantly expand the coverage of the company's products and services, particularly increasing penetration in public health and social welfare systems, creating notable social benefits while opening new market growth opportunities.
Finally, the collaboration with Beijing Jianguo Medical further strengthens Neural Aurora's cooperative network with national-level research institutions. The real-world data obtained from the long-term research cohorts will become a valuable asset driving the company's algorithm iterations, product optimizations, and innovative R&D.
After the successful promotion of this collaboration, digital therapies for cognitive disorders will become more standardized at the national level, facilitating large-scale promotion across the country. This important milestone will greatly support the company's revenue and profit prospects, so stay tuned for subsequent stock price performance.
$BRAINAURORA-B(06681.HK)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
